Helena Shen

Nov 8, 2023 | nature.com | Quinlen Marshall |John Warrington |Alvin Farrel |David Groff |Sarvind Tripathi |Son Nguyen | +3 more

AbstractThe majority of oncogenic drivers are intracellular proteins, constraining their immunotherapeutic targeting to mutated peptides (neoantigens) presented by individual human leukocyte antigen (HLA) allotypes1. However, most cancers have a modest mutational burden that is insufficient for generating responses using neoantigen-based therapies2,3. Neuroblastoma is a paediatric cancer that harbours few mutations and is instead driven by epigenetically deregulated transcriptional networks4.

Nov 8, 2023 | nature.com | Quinlen Marshall |Sarvind Tripathi |Son Nguyen |Dimiter S. Dimitrov |Helena Shen |Nathan Kendsersky

Retraction to: Nature https://doi.org/10.1038/s41586-021-04061-6 Published online 3 November 2021The authors are retracting this manuscript because of an important experimental error we detected. The manuscript reported tetramer staining experiments showing that 10LH can interact with multiple HLA allotypes including the HLA-B*14:02/PHOX2B peptide complex (Fig. 1a, 3c).